Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited

Sonja Loges; Massimiliano Mazzone; Philipp J. Hohensinner; Peter Carmeliet

doi:10.1016/j.ccr.2009.02.007

Back

Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited

Article 2009 en

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Letter2006

VEGF inhibitors make blood

Christian Fischer, Peter Carmeliet, Edward M. Conway

Article2009

VEGF‐D deficiency in mice does not affect embryonic or postnatal lymphangiogenesis but reduces lymphatic metastasis

Marta Koch, Daniela Dettori, An Van Nuffelen, Joris Souffreau, Lucia Marconcini, Goedele Wallays, Lieve Moons, Françoise Bruyére, Salvatore Oliviero, Agnès Noël, Jean‐Michel Foidart, Peter Carmeliet, Mieke Dewerchin

Editorial Material2024

Immune Checkpoint Inhibitors plus Anti-VEGF/Tyrosine Kinase Inhibitors Combined with TACE (Triple Therapy) in Unresectable Hepatocellular Carcinoma

Masatoshi Kudo

Article2006

VEGF inhibitors aggravate ALS, possibly by reducing neural perfusion

Koen Poesen, Koen Nelissen, Diether Lambrechts, Erik Storkebaum, Lieve Moons, Désiré Collen, Peter Carmeliet

Article2000

VEGF gene therapy: stimulating angiogenesis or angioma-genesis?

Peter Carmeliet